Fourpath Capital Management LLC Acquires 306 Shares of Novo Nordisk A/S (NYSE:NVO)

Fourpath Capital Management LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 10.2% in the fourth quarter, HoldingsChannel reports. The firm owned 3,306 shares of the company’s stock after purchasing an additional 306 shares during the period. Fourpath Capital Management LLC’s holdings in Novo Nordisk A/S were worth $284,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. DAVENPORT & Co LLC increased its stake in Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after purchasing an additional 451,641 shares in the last quarter. Wellington Management Group LLP acquired a new position in Novo Nordisk A/S during the third quarter worth $42,017,000. Finally, World Investment Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after buying an additional 270,234 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.1 %

Shares of NYSE:NVO opened at $82.60 on Wednesday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a market capitalization of $370.65 billion, a PE ratio of 26.73, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The business has a fifty day moving average price of $93.12 and a two-hundred day moving average price of $112.54. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of analyst reports. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.